Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that vibration anesthesia significantly reduced pain during botulinum toxin injections for masseter reduction without affecting the injection's diffusion or causing adverse effects, and high patient satisfaction was also reported.

This study suggests that a mild intramuscular dose of botulinum toxin improved spermatogenesis and sperm parameters in ageing mice.

This review reports that botulinum toxin is used in dermatology not only for treating rhytides but also for conditions like rosacea, hyperhidrosis, and menopause-related flushing, although its full safety and efficacy profile requires more research.

This review discusses the pathogenesis and treatment of hidradenitis suppurativa and examines botulinum toxin type A as a potential therapeutic option, but reports no new clinical results.

This study highlights the growing use of botulinum toxin in both medical and cosmetic fields, showing its benefits and risks. Proper administration is crucial to avoid severe side effects like muscle weakness and respiratory issues, emphasizing the need for enhanced safety measures and regulations.

This study reviews current trends and the state of research on botulinum toxin in dermatology, aiming to help researchers identify key areas and explore new research directions.

This case report suggests that intradermal botulinum toxin type A may alleviate pruritus and reduce papules in Fox-Fordyce disease, improving quality of life without serious adverse effects for at least six months.

This systematic review of five studies found that intradermal and intramuscular botulinum toxin injections showed promising hair growth outcomes for men with androgenic alopecia, but emphasizes caution due to a lack of control groups and small sample sizes.

The researchers reported that intralesional botulinum toxin A effectively alleviated pain associated with cutaneous leiomyomas in a patient with hereditary leiomyomatosis and renal cell cancer syndrome, with repeated treatments every three months maintaining pain relief over 1.5 years.

This review discusses the potential mechanisms by which intradermal botulinum toxin may affect androgenetic alopecia but notes that high-evidence clinical trials have yet to show conclusive results.

This study found that BOTOX doses of 75–100 U effectively reduce postvoiding residual urine and detrusor pressure in patients with detrusor sphincter dyssynergia.

This review examines current literature on botulinum toxin type A for androgenetic alopecia, reporting an association with increased hair growth and improved hair density, though further research is needed.

In this retrospective analysis, patients with trichodynia who were unresponsive to standard treatments showed significant symptom improvement after receiving intradermal botulinum toxin type A, with nearly all patients benefiting, particularly those with scarring alopecia.

This narrative review concluded that facial aging involves complex anatomical changes that require multimodal rejuvenation approaches, integrating fillers, collagen stimulators, botulinum toxin, and energy-based devices for effective results, while emphasizing the need for scientific evidence and patient safety in aesthetic treatments.

In this randomized controlled trial, both Botulinum Toxin-A and Triamcinolone Acetonide showed substantial effectiveness in treating patchy Alopecia Areata, but Botulinum Toxin-A avoided complications while Triamcinolone led to skin atrophy in 16.7% of patients.

In this systematic review and meta‐analysis, botulinum toxin monotherapy was found to significantly increase hair density in patients with androgenetic alopecia, with optimal effects observed using a 100-unit dose every six months. These findings suggest potential efficacy but should be confirmed in larger, placebo-controlled trials.

In this review, BTXA treatment was reported to effectively increase hair density and improve follicle health in androgenetic alopecia patients by enhancing scalp blood flow and reducing inflammation, without significant adverse effects.

This registered trial will investigate whether preoperative botulinum toxin can improve hair transplantation outcomes by enhancing blood flow and reducing ischemia in the scalp.

This article outlines a randomized trial to evaluate whether preoperative botulinum toxin administration can improve hair transplantation outcomes by reducing ischemia-induced graft failure.

In this review, researchers examined nine studies on botulinum toxin type A's effects on biomarkers in chronic head and neck conditions, finding significant, though low to moderate certainty, changes in markers like CGRP and serotonin associated with inflammation and mood disorders.

This study outlines a randomized trial investigating the effects of botulinum toxin administered before hair transplantation to potentially improve outcomes by enhancing blood flow and reducing graft failure due to ischemia in androgenetic alopecia patients.

In this study, combining Botulinum toxin type A with Platelet-rich plasma was found to enhance hair follicle growth and reconstruction, potentially through inflammation reduction and activation of the Wnt/β-catenin pathway via STMN1 protein modulation.

This study outlines a randomized trial to assess if administering botulinum toxin before hair transplantation can improve outcomes by enhancing blood flow and reducing ischemia-induced graft failure in patients with androgenetic alopecia.

This study explores the hypothesis that preoperative administration of botulinum toxin could enhance hair transplantation outcomes by improving scalp microenvironment and reducing ischemia-induced graft failure, using a randomized split-scalp controlled trial design.

In this study, researchers found that type A botulinum toxin injections can reduce hypertrophic scars effectively, though more high-quality studies are needed to confirm the precision and stability of these therapeutic effects.

Botulinum toxins show promise in treating various conditions, but more research is needed for hair and scalp disorders.

This review reports that while botulinum toxin shows potential mechanisms for treating androgenetic alopecia, recent high-quality trials found no significant hair density improvement compared to placebo, indicating it can't yet replace traditional treatments.

This review reported that "Social Botox," encompassing both BTX cosmetic use and societal beauty pressures, significantly influences adolescent self-image, driven by social media and cultural standards, with mixed psychological outcomes, potentially enhancing confidence or exacerbating body dissatisfaction across various cultures.

This paper highlights the emerging trend of treating androgenic alopecia with botulinum toxin, despite insufficient scientific evidence supporting its effectiveness.

This study found that both intralesional minoxidil 8% and botulinum toxin type A were equally effective in treating female pattern hair loss, with no significant difference in results between the two treatments.